NCT04388254 - Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions

Alzheimer Disease

Interventions

DRUG

Simufilam 100 mg oral tablet

Simufilam 100 mg oral tablet for b.i.d. administration

DRUG

Placebo

Matching placebo oral tablets

Trial Locations (17)

33016

Adaptive Clinical Research, Inc, Miami Lakes

33125

Optimus U, Miami

33157

IMIC, Inc., Palmetto Bay

33445

Brain Matters Research, Delray Beach

33912

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

44720

Neuro-Behavioral Clinical Research, North Canton

68005

Cognitive Clinical Trials, Bellevue

68130

Cognitive Clinical Trials, Omaha

77058

Centex Studies, Inc., Houston

78504

Centex Studies, McAllen

78757

Senior Adults Specialty Research, Austin

85296

Cognitive Clinical Trials, Gilbert

85374

Cognitive Clinical Trials, Surprise

92251

Sun Valley Research Center, Inc., Imperial

08755

Advanced Memory Research Institute, Toms River

K1Z 1G3

Ottawa Memory Clinic, Ottawa

M3B 2S7

Toronto Memory Program, Toronto